Lercanidipine Accord

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Accord, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adults with primary hypertension and is prescribed by physicians for long‑term cardiovascular risk management.

GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global distribution. Our network facilitates timely delivery and supports pharmacovigilance initiatives across diverse markets.

Lercanidipine is indicated for the management of hypertension, acting on the vascular smooth‑muscle calcium channels to achieve blood‑pressure control.

- Essential hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk profile. - Primary hypertension: provides sustained antihypertensive effect with once‑daily dosing for better patient adherence. - Mild to moderate hypertension: achieves target blood pressure levels when monotherapy is appropriate.

Adverse reactions may occur with any antihypertensive therapy. Most are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, usually resolves with continued use. - Peripheral edema: swelling of ankles or feet, may improve with dose adjustment. - Dizziness: especially upon standing, related to blood‑pressure changes. - Tachycardia: increased heart rate, generally mild. - Palpitations: awareness of heartbeat, often benign.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Myocardial infarction: rare but possible in susceptible patients. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms that may need monitoring.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks. - Renal impairment: assess kidney function and monitor blood pressure closely. - Hepatic impairment: use with caution; liver function tests may be warranted. - Concomitant antihypertensives: watch for additive hypotensive effects. - Elderly patients: start at the lowest effective dose to reduce adverse events. - Pregnancy: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering, monitor for hypotension. - Grapefruit juice: can raise lercanidipine levels, advise moderation. - Simvastatin or other statins metabolized by CYP3A4: increased risk of myopathy, consider dose adjustment.